Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has received the go-ahead from an independent data safety monitoring committee (DSMC) to enroll the final 24 patients in its first-in-human U.S. clinical study of IDCT, an allogeneic, injectable disc cell therapy for mild to moderate degenerative disc disease (DDD).

The DSMC completed a third and final planned mid-trial safety review following treatment of the first six subjects in the high dose study cohort, each of whom was treated based on random assignment into one of three arms: high dose IDCT study treatment, vehicle or placebo.

The DSMC reported there were no safety issues and recommended that the study proceed with completion of patient enrollment with no changes to the protocol.

This news closely follows a recent company announcement that the second planned safety review of the first 30-subject low dose study cohort revealed no safety issues.

“We are delighted to commence the final enrollment stage in our U.S. study of IDCT for DDD and are thrilled that the first 36 patients have now been safely treated,” said Flagg Flanagan, Chief Executive Officer and Chairman of the Board of Directors for DiscGenics. “This is a blinded, first-in-human study where neither the treating clinicians nor the patients know what treatment is being administered. As a result, performance of periodic safety checks by an unblinded and independent body was essential to ensuring the ongoing safety of IDCT in a clinical setting. The members of the DSMC played a critical role in this process and we would like to sincerely thank them for their time and thoughtful review of the blinded safety data.”

Patient enrollment in this U.S. study will now continue through completion of 60 total subjects.

spot_img

DON'T MISS

Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.